Elevated CEA and CA 19-9 Levels within the Normal Ranges Increase the Likelihood of CRC Recurrence in the Chinese Han Population

Wang, Lujia; Zhang, Guangkai; Shen, Jiafeng; Shen, Y; Cai, Guojun

doi:10.1155/2022/8666724

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in the validation cohort, C1 status was associated with an almost 50% increase in overall and cancer-specific mortalities. These findings are consistent with those of previous studies and strongly suggest that serum CEA level can serve as an independent prognostic factor in patients with CRC ( 5 , 10 , 19 – 21 ).…”

Section: Discussionsupporting

confidence: 93%

The value of carcinoembryonic antigen stage in staging, prognosis, and management of colorectal cancer: results from two cohort studies

Xie,

Wei,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundCombining the carcinoembryonic antigen (CEA) level (C stage) with TNM staging can provide a more comprehensive prognostic assessment of colorectal cancer (CRC). However, the clinical value of incorporating CEA status into the TNM staging system needs to be evaluated.MethodsWe used the SEER database (N = 49,350) and a retrospective cohort from China (N = 1,440). A normal CEA level was staged as C0 and an elevated CEA level was staged as C1. Restricted cubic spline analysis was used to examine the dose-response relationship between the CEA level and survival. The Kaplan-Meier method with the log-rank test was used to plot survival curves. Multivariable Cox proportional hazards regression models with forward stepwise variable selection were used to estimate the hazard ratios and 95% confidence intervals.ResultsPatients with C1 were more likely to have advanced disease than those with C0. CEA on a continuous scale was positively associated with mortality risk. Compared with patients with C0 stage, those with C1 stage had significantly lower survival rates. In the SEER dataset, C1 was independently associated with poor prognosis in patients with CRC, with an approximately 70% increased risk of mortality. Patients with C1 stage had significantly lower survival than those with C0 stage at all clinical stages. Incorporating the C stage into the TNM staging refined the prediction of prognosis of patients with CRC, with a gradual decline in prognosis from stage I C0 to stage IV C1. A similar pattern was observed in the present retrospective cohort study. At each lymph node stage, patients with C1 had significantly lower 5-year survival rates than patients with C0. Compared with lymph node positivity, CEA positivity may have a stronger correlation with a worse prognosis.ConclusionOur findings not only validated the independent prognostic significance of CEA in CRC but also demonstrated its enhanced prognostic value when combined with TNM staging. Our study provides evidence supporting the inclusion of C stage in the TNM staging system.

show abstract

Section: Discussionsupporting

confidence: 93%

The value of carcinoembryonic antigen stage in staging, prognosis, and management of colorectal cancer: results from two cohort studies

Xie,

Wei,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…It is highly expressed in CRC cells and is a potential target for CRC treatment. 136 , 137 In a phase I clinical trial on CEA, three mCRC patients received the CAR-T treatment, and their serum CEA levels decreased significantly. One patient had lung metastasis and liver metastasis, and all patients had severe colitis.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Li¹,

Xu²

2023

IJGM

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body's autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/ microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.

show abstract

“…Overexpression of CEA or CA 19-9 both indicated higher tumor recurrence in patients, which was applied to diagnose and provide guidelines for CRC patients. ( 19 ) Kasanga et al ( 20 ) reported the combination of CEA, CA 19-9, and Hsp90α together could help to distinguish early-staged CRC. They found the levels of Hsp90α were significantly higher in advanced CRCs (stage III and IV) compared to CRC I and CRC II because they could promote cell proliferation and cell apoptosis.…”

Section: Introductionmentioning

confidence: 99%

Metabolomics analysis of amino acid and fatty acids in colorectal cancer patients based on tandem mass spectrometry

Zhao,

Bai,

Liu

et al. 2023

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

Metabolic differences between colorectal cancer (CRC) and NI (NI) play an important role in early diagnoses and in-time treatments. We investigated the metabolic alterations between CRC patients and NI, and identified some potential biomarkers, and these biomarkers might be used as indicators for diagnosis of CRC. In this study, there were 79 NI, 50 CRC I patients, 52 CRC II patients, 56 CRC III patients, and 52 CRC IV patients. MS-MS was used to measure the metabolic alterations. Univariate and multivariate data analysis and metabolic pathway analysis were applied to analyze metabolic data and determine differential metabolites. These indicators revealed that amino acid and fatty acids could separate these groups. Several metabolites indicated an excellent variables capability in the separation of CRC patients and NI. Ornithine, arginine, octadecanoyl carnitine, palmitoyl carnitine, adipoyl carnitine, and butyryl carnitine/propanoyl carnitine were selected to distinguish the CRC patients and NI. And methionine and propanoyl carnitine, were directly linked to different stages of CRC. Receiver operating characteristics curves and variables importance in projection both represented an excellent performance of these metabolites. In conclusion, we assessed the difference between CRC patients and NI, which supports guidelines for an early diagnosis and effective treatment.

show abstract

Elevated CEA and CA 19-9 Levels within the Normal Ranges Increase the Likelihood of CRC Recurrence in the Chinese Han Population

Cited by 7 publications

References 21 publications

The value of carcinoembryonic antigen stage in staging, prognosis, and management of colorectal cancer: results from two cohort studies

The value of carcinoembryonic antigen stage in staging, prognosis, and management of colorectal cancer: results from two cohort studies

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Metabolomics analysis of amino acid and fatty acids in colorectal cancer patients based on tandem mass spectrometry

Contact Info

Product

Resources

About